Cure8 research brief
An Expression of Concern signals potential problems with a preclinical IBD study’s data or images. Patients and clinicians should be cautious about relying on that specific animal-study finding when considering complementary therapies or interpreting the literature.
Researchers who follow preclinical IBD models, clinicians who track translational evidence, and patients interested in herbal or complementary therapies for IBD.
The publisher has issued an Expression of Concern (not a retraction) because of questions raised on PubPeer about duplicated or highly similar histopathology images and microscopic scoring reported in this and related papers by the same group.
The journal investigated but could not retrieve original raw data (likely due to the age of the study), so it could not definitively determine the impact on the study’s conclusions. If you previously read or cited the 2006 study reporting benefits of Zataria multiflora in a mouse IBD model, treat its findings cautiously until a full resolution is available.
The authors have been notified and the publisher has informed readers via this notice.
This notice concerns a 2006 animal study and was issued after third-party scrutiny on PubPeer; the publisher could not obtain raw data due to the article’s age and thus could not conclusively determine whether the concerns change the paper’s conclusions. An Expression of Concern is not the same as a retraction.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
